×
+ All Categories
Log in
English
Français
Español
Deutsch
The top documents tagged [response duration]
Home >
response duration
[Day 2] Center Presentation: WFP
464 views
Dr. Gopichand Pendurti M.B.B.S ACTIVITY OF RITUXIMAB AND OFATUMUMAB AGAINST MANTLE CELL LYMPHOMA(MCL) IN VITRO IN MCL CELL LINES BY COMPLEMENT DEPENDENT.
213 views
Multiple Myeloma: ASH 2005 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine.
216 views
Steele Taylor presents: A Neuro-Endocrine Approach to The Obstetric and Pediatric Applications of Tactile-Kinesthetic Stimulation Therapy questions/complaints:
222 views
Differential Reinforcement & Differential Punishment Chapter 7.
230 views
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent.
215 views
STN 125011 Tositumomab Therapeutic Regimen (TTR) [tositumomab plus I-131 tositumomab] Oncologic Drugs Advisory Committee December 17, 2002.
214 views
Update: Non-Hodgkin’s Lymphoma 20082008. ICML 2008: Update on non-Hodgkin’s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients.
224 views
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance.
216 views
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
229 views
FDA Review : Cisplatin / Epinephrine Gel (CEG) in the Treatment of Head and Neck Cancer.
218 views
Presented By Mario Sznol at 2014 ASCO Annual Meeting
67 views
Next >